Genscript Biotech Corporation
1548
Classificação em ações
#2120
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Preço da ação
$4.32
Valor de mercado
$9.72B
Variação (1 dia)
1.14%
Variação (1 ano)
107.18%
País
HK
Negociar Genscript Biotech Corporation (1548)
Categoria
Healthcare
Lucros da Genscript Biotech Corporation (1548)
Lucros em Jun 2026 TTM: $-589.54M
De acordo com os últimos relatórios financeiros da Genscript Biotech Corporation, os ganhos atuais da empresa são de $-589.54M. Em 2023, a empresa teve ganhos de $-350.98M, um aumento em relação a aos ganhos de 2022, que foram de $-431.69M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Genscript Biotech Corporation de 2013 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $-589.54M | 245.17% |
| 2024 | $-170.80M | -51.34% |
| 2023 | $-350.98M | -18.70% |
| 2022 | $-431.69M | -16.56% |
| 2021 | $-517.36M | 83.53% |
| 2020 | $-281.90M | 147.95% |
| 2019 | $-113.69M | -600.84% |
| 2018 | $22.70M | -41.07% |
| 2017 | $38.52M | 18.49% |
| 2016 | $32.51M | 41.49% |
| 2015 | $22.98M | 193.21% |
| 2014 | $7.84M | 4.08% |
| 2013 | $7.53M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | -994.74% |
US
|
|
| $-3.09B | 423.62% |
US
|
|
| $-4.02B | 581.24% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -430.87% |
NL
|
